Vehicle Safety
Recalls Search 320,000+ NHTSA safety recalls Complaints 2.1M+ consumer safety complaints TSBs 4.7M technical service bulletins VIN Lookup Decode any vehicle VIN instantly OBD Codes 12,000+ diagnostic trouble codes Fuel Economy EPA MPG data for all vehicles Statistics Recall trends & safety analysis
Consumer Safety
Product Safety 9,700+ CPSC product recalls Food Safety 28,600+ FDA food recalls Pet Safety 1.3M FDA animal adverse events Drug Safety 17,500+ FDA drug recalls Device Safety 38,400+ FDA device recalls Workplace Safety 102,900+ OSHA injury reports
Infrastructure
Bridge Safety 624,000 bridge inspections Aviation Safety 30,000+ NTSB aviation events Dam Safety 92,600 dam safety records Water Safety 433,000+ public water systems Railroad Safety 438,000+ rail crossings Pipeline Safety 8,800+ pipeline incidents
Public Health
Nursing Homes 14,700 CMS rated facilities Environmental 80,000+ hazardous sites & releases

Browse Drug Recalls

305 FDA drug safety recalls.

FDA Drug Recall Enforcement Database

Browse 305 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.

Drug Safety Recalls

Browse 305 FDA drug recalls.

Clear
DateProductReasonClassFirm
Feb 15, 2021 Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 25x2mL Single Dose Vials,... Chemical contamination; Unknown brown residue adhering to the inside of one vial. Class II Teva Pharmaceuticals USA
Feb 10, 2021 MethyIPREDNISolone Acetate Injectable Suspension USP, 200 mg/5 mL (0 mg/mL), ... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Leucovorin Calcium for Injection, USP, 100 mg/vial, Single-Dose Vial, Rx only... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Leucovorin Calcium for Injection, USP, 350 mg/vial, Rx only, labeled as a) Te... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/10 mL (40 mg/mL)... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 MethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/5 mL (80 mg/mL),... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Epoprostenol Sodium for Injection, 0.5 mg/vial (500,000 ng), 1X10ML vial, Rx... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Toposar (etoposide injection USP), 1 gram/50 mL (20 mg/mL), 50 mL Multiple-do... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 MethyIPREDNISolone Acetate Injectable Suspension USP, 80 mg/mL, 1 mL Single-D... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 MethyIPREDNISolone Acetate Injectable Suspension USP, 40 mg/mL, 1 mL Single... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Vecuronium Bromide for Injection, 10 mg, 1 mg/mL when reconstituted to 10 mL,... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Dacarbazine for Injection USP, 200 mg, Single Use Vial (NDC 0703-5075-01), pa... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Desmopressin Acetate Injection USP, 4 mcg/mL, 1 mL Preserved Vial (NDC 0703-5... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Sterile Diluent for Epoprostenol Sodium for Injection, 50 mL vial (NDC 0703-9... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 2 mL Single-Use Vial NDC ... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Feb 10, 2021 Epoprostenol Sodium for Injection, 1.5 mg/vial (1,500,000 ng), 10 mL vial, Rx... Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance... Class II Teva Pharmaceuticals USA
Nov 11, 2020 Testosterone Gel 1%, 2.5 grams per unit dose, packaged in 2.5 gram Unit-Dose ... Superpotent Drug: High out-of-specification assay results were obtained during stability testing. Class III Teva Pharmaceuticals USA
Oct 28, 2020 Mesalamine Delayed-Release Tablets, USP 1.2 gram, 120 tablets per bottle, Rx ... Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during ... Class II Teva Pharmaceuticals USA
Sep 4, 2020 Buprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal... Failed Stability Specifications: Below specification result for buprenorphine release rate. Class II Teva Pharmaceuticals USA
Aug 24, 2020 Cephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For ... Sub-Potent Drug: Out of specification test results for potency (below specification). Class II Teva Pharmaceuticals USA
Aug 24, 2020 Cephalexin for Oral Suspension, USP 125 mg per 5 mL, For Reconstitution, For ... CGMP deviations; there is a possibility that some bottles in these lots may have the active ingre... Class II Teva Pharmaceuticals USA
Aug 24, 2020 Cephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For ... CGMP deviations; there is a possibility that some bottles in these lots may have the active ingre... Class II Teva Pharmaceuticals USA
Jul 14, 2020 Lidocaine Patch 5%, packaged in 30-count cartons, Rx only, Manufactured by: A... Labeling: Incorrect or Missing Lot and/or Exp date on the individual transdermal pouches but not ... Class II Teva Pharmaceuticals USA
Jun 2, 2020 Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, a) 100 (NDC 620... CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptabl... Class II Teva Pharmaceuticals USA
Jun 2, 2020 Metformin Hydrochloride Extended - Release Tablets, USP, 500 mg, a) 100 (NDC ... CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptabl... Class II Teva Pharmaceuticals USA
May 22, 2020 Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfat... Some bottles may contain mixed strengths of the product. Class II Teva Pharmaceuticals USA
May 22, 2020 Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfat... Some bottles may contain mixed strengths of the product. Class II Teva Pharmaceuticals USA
May 22, 2020 Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfat... Some bottles may contain mixed strengths of the product. Class II Teva Pharmaceuticals USA
Mar 25, 2020 LOSARTAN POTASSIUM TABLETS, USP 25 mg, Bulk, Rx only, For Further Manufacturi... CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the activ... Class II Teva Pharmaceuticals USA
Mar 25, 2020 LOSARTAN POTASSIUM TABLETS, USP 100 mg, Bulk, Rx only, For Further Manufactur... CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the activ... Class II Teva Pharmaceuticals USA
Mar 25, 2020 LOSARTAN POTASSIUM TABLETS, USP 50 mg, Bulk, Rx only, For Further Manufactur... CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the activ... Class II Teva Pharmaceuticals USA
Mar 5, 2020 Epinephrine Injection USP, 0.3 mg (Auto-Injector), 0.3 mg/ 0.3 mL pre-filled ... CGMP Deviations: Precautions taken due to Out-of-specification for trigger force for a non-market... Class II Teva Pharmaceuticals USA
Feb 20, 2020 Mesalamine Delayed-Release Tablets, USP, 1.2 gram, 120-count bottle, Rx Only,... Failed Dissolution Specifications: Low out of specification dissolution result observed during st... Class II Teva Pharmaceuticals USA
Jan 28, 2020 Tramadol Hydrochloride Tablets USP CIV, 50 mg, packaged in a) 100-count bottl... Labeling: Incorrect package insert - Patient leaflets for the specified lots of unscored tablets ... Class III Teva Pharmaceuticals USA
Jan 27, 2020 Methylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-c... CGMP deviations: Product bottle may be absent of desiccant. Class II Teva Pharmaceuticals USA
Jan 27, 2020 Desmopressin Acetate Tablets, 0.2 mg, 100-count bottle, Rx Only, Manufactured... GMP Deviations: Product bottle may be absent of desiccant. Class II Teva Pharmaceuticals USA
Jan 27, 2020 Methylphenidate hydrochloride Extended-Release ablets USP (CII), 27 mg, 100-c... CGMP deviations: Product bottle may be absent of desiccant. Class II Teva Pharmaceuticals USA
Jan 27, 2020 Desmopressin Acetate Tablets, 0.1 mg, 100-count bottle, Rx Only, Manufactured... GMP Deviations: Product bottle may be absent of desiccant. Class II Teva Pharmaceuticals USA
Nov 4, 2019 Valganciclovir Hydrochloride for Oral Solution, 50 mg/mL, 100 mL (3.4 fl. oz.... Presence of foreign substance: Brown/black particles found during stability testing. Class II Teva Pharmaceuticals USA, Inc.
Sep 6, 2019 Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30 coun... GMP Deviation: lot not intended for commercial distribution. Class III Teva Pharmaceuticals USA
Jun 6, 2019 LOSARTAN POTASSIUM 100 mg TABLET BULK 90 count bottles, NDC 00591-3747-00 CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the activ... Class II Teva Pharmaceuticals USA
Jun 6, 2019 LOSARTAN POTASSIUM 50 mg TABLET BULK 90 count bottles and 1000 count bottles... CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the activ... Class II Teva Pharmaceuticals USA
Apr 12, 2019 Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL ... Subpotent Product: assay results for Amoxicillin were below the specification limits. Class II Teva Pharmaceuticals USA
Mar 11, 2019 Lansoprazole Delayed-Release Orally Disintegrating Tablets, 15 mg, 100 tablet... Subpotent Drug. Class III Teva Pharmaceuticals USA
Dec 19, 2018 Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 40 mg/25 mg, packaged i... Failed dissolution specifications Class II Teva Pharmaceuticals USA
Nov 27, 2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 5 mg/160 mg/12.5 mg, ... CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... Class II Teva Pharmaceuticals USA
Nov 27, 2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/25 mg, (... CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... Class II Teva Pharmaceuticals USA
Nov 27, 2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/160 mg/12.5 mg, ... CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... Class II Teva Pharmaceuticals USA
Nov 27, 2018 Amlodipine and Valsartan Tablets 10 mg/160 mg, (a) 30-count bottles (NDC 0093... CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... Class II Teva Pharmaceuticals USA
Nov 27, 2018 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 10 mg/320 mg/25 mg, (... CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine... Class II Teva Pharmaceuticals USA

Frequently Asked Questions

When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.

The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.

Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.